These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35220214)

  • 1. Death Receptor 6 as a Prognostic Marker in Low-grade Glioma.
    Stegmann SK; Kuhl S; Im NG; Diem-Dinh DT; Goertz L; Goldbrunner R; Timmer M
    Anticancer Res; 2022 Mar; 42(3):1237-1245. PubMed ID: 35220214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Death Receptor 6 (DR6) Is Overexpressed in Astrocytomas.
    Stegmann S; Werner JM; Kuhl S; Röhn G; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
    Anticancer Res; 2019 May; 39(5):2299-2306. PubMed ID: 31092421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
    Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
    World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
    Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
    J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
    Patil V; Mahalingam K
    Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of FAS-L Differs from Primary to Relapsed Low-grade Gliomas and Predicts Progression-free Survival.
    Werner JM; Kuhl S; Stavrinou P; Röhn G; Krischek B; Blau T; Goldbrunner R; Timmer M
    Anticancer Res; 2017 Dec; 37(12):6639-6648. PubMed ID: 29187439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic screening identifies GABRD, a subunit gene of GABAA receptor as a prognostic marker in adult IDH wild-type diffuse low-grade glioma.
    Zhang H; Zhang L; Tang Y; Wang C; Chen Y; Shu J; Zhang K
    Biomed Pharmacother; 2019 Oct; 118():109215. PubMed ID: 31545245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deconvolution and network analysis of IDH-mutant lower grade glioma predict recurrence and indicate therapeutic targets.
    Li G; Jiang Y; Lyu X; Cai Y; Zhang M; Wang Z; Li G; Qiao Q
    Epigenomics; 2019 Aug; 11(11):1323-1333. PubMed ID: 31272213
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic Role of Chicken Ovalbumin Upstream Promoter Transcription Factor II in Isocitrate Dehydrogenase-Mutant Glioma with 1p19q Co-Deletion.
    Chai Y; Liu W; Wang C; Rao M; Zhang Y
    J Mol Neurosci; 2019 Jun; 68(2):234-242. PubMed ID: 30929126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-omics analysis-based model to predict the prognosis of low-grade gliomas.
    Du Z; Jiang Y; Yang Y; Kang X; Yan J; Liu B; Yang M
    Sci Rep; 2024 Apr; 14(1):9427. PubMed ID: 38658591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma.
    Sun Y; Sedgwick AJ; Palarasah Y; Mangiola S; Barrow AD
    Front Immunol; 2021; 12():668391. PubMed ID: 34539622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of Immune-Related lncRNA SBF2-AS1 in Diffuse Lower-Grade Glioma.
    Zhang Q; Liu XJ; Li Y; Ying XW; Chen L
    Technol Cancer Res Treat; 2021; 20():15330338211011966. PubMed ID: 34159865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACTC1 as an invasion and prognosis marker in glioma.
    Ohtaki S; Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Noshiro S; Akiyama Y; Mikami T; Mikuni N; Kocsis JD; Honmou O
    J Neurosurg; 2017 Feb; 126(2):467-475. PubMed ID: 27081897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
    Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
    Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a nomogram for prognostic prediction of lower-grade glioma based on alternative splicing signatures.
    Wang Y; Wang Z; Zhao B; Chen W; Wang Y; Ma W
    Cancer Med; 2020 Dec; 9(24):9266-9281. PubMed ID: 33047900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas.
    Nakashima S; Sugita Y; Miyoshi H; Arakawa F; Muta H; Ishibashi Y; Niino D; Ohshima K; Terasaki M; Nakamura Y; Morioka M
    J Neurooncol; 2016 Mar; 127(1):23-32. PubMed ID: 26645886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.